Developing nanoparticles to overcome chemotherapy resistance in ovarian cancer
Targeting Fluid Stress-induced Chemoresistance in a 3D Carcinomatosis Perfusion Model Using Mechanism-based Photo-immunoconjugate Nanoparticles
This study is looking at how advanced ovarian cancer behaves and responds to treatments by using a special 3D model, and it's testing new tiny particles that could make a light-based therapy work better, which might help patients get more effective treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-11001518 on NIH RePORTER |
What this research studies
This research focuses on advanced ovarian cancer, which often resists standard chemotherapy treatments. By creating a 3D model that mimics the environment of ovarian tumors, researchers aim to understand how fluid dynamics affect cancer cell behavior and treatment response. The study explores the use of specially designed nanoparticles that can enhance the effectiveness of photoimmunotherapy, a technique that targets and treats cancer cells. Patients may benefit from new therapies that could improve their response to chemotherapy and overall treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced or recurrent ovarian cancer who have shown resistance to standard chemotherapy.
Not a fit: Patients with early-stage ovarian cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with chemotherapy-resistant ovarian cancer.
How similar studies have performed: Previous research has shown promise in using nanoparticles and photoimmunotherapy for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: Huang, Huang Chiao — Univ of Maryland, College Park
- Study coordinator: Huang, Huang Chiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.